Therapeutic Response

RET oncogenic variants status confers therapeutic sensitivity to Selpercatinib in patients with Medullary Thyroid Cancer.

Statements

Source and description
Retevmo (selpercatinib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to selpercatinib for the treatment of adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy.
Retevmo (selpercatinib) [product monograph]. HC. Health Canada approved selpercatinib as monotherapy for the treatment of RET-mutant medullary thyroid cancer (MTC) in adult and pediatric patients 12 years of age and older with unresectable advanced or metastatic disease.